ABILITYPHARMA

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing autophagy by binding receptors PPARα/γ

ONE MILLION € CROWDFUNDING CAMPAIGN WITH CAPITAL CELL STARTING ON SEPTEMBER 12, 2018.

PHASE 2 CLINICAL TRIAL ONGOING AS FIRST-LINE THERAPY IN PATIENT WITH EITHER ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER. PATIENTS BEING RECRUITED AT VALL D'HEBRON INSTITUT D'ONCOLOGIA VHIO (BARCELONA), INSTITUT GUSTAVE ROUSSY IGR (PARIS), INSTITUT CATALÀ D'ONCOLOGIA ICO (L’HOSPITALET, BADALONA AND GIRONA), CENTRE LÉON BÉRARD (LYON), INCLIVA (VALENCIA), INSTITUT PAOLI-CALMETTES (MARSEILLE) AND HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (SEVILLE).

http://capitalcell.es/campaign/ability-pharmaceuticals

AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. The company was established in 2009 with one product, ABTL0812, an oral autophagy-inducer targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC.

Media Center

19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
14.12.2017

Events

2018 + info
06.02.2017

Events

2017 + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG